Angiogenesis is the process of new vessel formation, which sprouts from preexisting vessels. This process is highly complex and primarily involves several key steps, including stimulation of endothelial cells by growth factors, degradation of the extracellular matrix by proteolytic enzymes, migration and proliferation of endothelial cells, and capillary tube formation. Currently, it is considered that multiple cytokines play a vital role in this process, which consist of proangiogenic factors (e.g., vascular endothelial growth factor, fibroblast growth factors, and angiopoietins) and antiangiogenic factors (e.g., endostatin, thrombospondin, and angiostatin). Angiogenesis is essential for most physiological events, such as body growth and development, tissue repair, and wound healing. However, uncontrolled neovascularization may contribute to angiogenic disorders. In physiological conditions, the above promoters and inhibitors function in a coordinated way to induce and sustain angiogenesis within a limited period of time. Conversely, the imbalance between proangiogenic and antiangiogenic factors could cause pathological angiogenesis and trigger several diseases. With insights into the molecular mechanisms of angiogenesis, increasing reports have shown that a close relationship exists between angiogenesis and oxidative stress (OS) in both physiological and pathological conditions. OS, an imbalance between prooxidant and antioxidant systems, is a cause and consequence of many vascular complains and serves as one of the biomarkers for these diseases. Furthermore, emerging evidence supports that OS and angiogenesis play vital roles in many dermatoses, such as psoriasis, atopic dermatitis, and skin tumor. This review summarizes recent findings on the role of OS as a trigger of angiogenesis in skin disorders, highlights newly identified mechanisms, and introduces the antiangiogenic and antioxidant therapeutic strategies.
1. Introduction
The complex process, regulated by proangiogenic and antiangiogenic factors, scientifically understood as the beginning formation of new blood vessels from existing ones, is known as angiogenesis [1]. New blood vessel formation, based on the balance of proangiogenic and antiangiogenic factors, is overwhelmingly responsible for most physiological events, such as embryogenesis, organ regeneration, body growth and development, skin renewal, and wound healing [2–4]. In the skin, angiogenesis is reactivated during skin renewal, wound healing, and tissue repair; furthermore, in these conditions, many angiogenic factors are released by activated keratinocytes and some inflammatory cells and jointly function to promote skin recovery and rejuvenation [5]; however, this process may be impaired by excessive angiogenic factors. In certain pathological conditions, these factors become overmuch and the balance between angiogenic promoters and inhibitors shifts, resulting in an angiogenic switch. The most well-known conditions where this switch is seen are malignant and inflammatory skin disorders as well as other pathological events, e.g., age-related macular degeneration, rheumatoid arthritis, tumor growth, proliferative retinopathies, and skin diseases (psoriasis, atopic dermatitis (AD), systemic sclerosis (SSc), cutaneous carcinoma, etc.) [5–8]. Either physiological or pathological angiogenesis is in need of initial mediation by various proangiogenic factors, consisting of endothelial growth factor (VEGF), fibroblast growth factors (FGF), interleukin-8 (IL-8), platelet-derived growth factor (PDGF), placental growth factor (PGF), angiopoietin-1 (Ang-1), and transforming growth factor-β (TGF-β) [9]. These proangiogenic factors subsequently induce a continuous recruitment of inflammatory cells to participate in the pathological process, which in turn serve as a substantial source of reactive oxygen species (ROS) [10, 11]. More importantly, excessive ROS trigger oxidative stress (OS), further promoting angiogenesis, damaging cells/tissue, and resulting in a variety of pathological changes [12].
OS is frequently considered as an imbalance of redox originating from the overproduction of prooxidants (e.g., ROS, reactive nitrogen species (RNS), nitric oxide (NO), and lipid peroxides) or from the insufficiency of antioxidants/antioxidant enzymes, like superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) (Figure 1) [13, 14]. Although the definition of OS is controversial, OS is currently regarded as a state in which stationary ROS/RNS transiently or gradually accumulate and ascend, further damaging cellular constituents and disturbing cellular metabolism [15]. Based on its intensity, OS is classified as basal OS (BOS), low-intensity OS (LOS), intermediate intensity OS (IOS), and high-intensity OS (HOS). OS, meanwhile, is categorized as mild OS (MOS), temperate OS (TOS), and severe OS (SOS) according to its degree [16]. In the process of OS, multiple redox signaling pathways are involved, primarily containing the mitogen-activated protein kinases/activator protein-1 (MAPK/AP-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Janus kinase-signal transducer and activator of transcription (JAK-STAT), nuclear factor erythroid 2-related factor (Nrf-2), phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), and Toll-like receptor- (TLR-) mediated signal transduction pathway [17]. Through these signaling pathways, OS mediates in physiological or pathological events. For example, MOS contribute to cell survival, whereas SOS may damage macromolecules (DNA, proteins, and lipids) and organelles (mitochondria and membranes), even the whole tissues (Figure 1) [18]. ROS, the major contributors to OS, including oxygen-centered radical species (superoxide anion (O2•-), hydroxyl radical (•OH), and peroxyl radical (R-O2•)) and nonradical compounds (ozone (O3), hypochlorous acid (HOCl), and hydrogen peroxide (H2O2)), are often generated by various categories of cells like endothelial cells (ECs), perivascular adipocytes, epithelial cells, smooth muscle cells, and adventitial fibroblasts [17]. In a physiological context, ROS have important roles in cell/tissue physiological processes including cell signaling, homeostasis, skin regeneration/renewal, and wound healing. In the skin in particular, ROS are mainly responsible for cell damage in the ageing process. ROS in low concentrations, nevertheless, participate in a substantial number of physiological cell redox signaling pathways to maintain redox equilibrium [19]; more importantly, ROS generated from immune cells are potently available for host defense [20]. As germicides or an important player in cellular signaling, they are also vital to wound healing and skin repair, while high-level ROS create a redox imbalance in the skin further causing severe “oxidative stress,” eventually leading to DNA, cell, and tissue damage [21–27]. Several studies have demonstrated that in high concentration, H2O2 could induce endothelial injury; however, H2O2 in low concentration generally stimulates angiogenesis in wound healing and skin repair [28]. Accumulating evidence also supports that ROS as well ROS-mediated OS are involved in the process of physiological and pathological angiogenesis [29, 30] and closely implicated in the pathogenesis and exacerbation of angiogenesis-related diseases containing dermatoses, neurodegenerative disorders, cardiovascular diseases, and metabolic disorders [31–38]. In this review, we provide an overview of the current knowledge of the link between OS and angiogenesis and their roles in certain skin diseases as well as the emerging therapeutic strategies.
The process of oxidative stress (OS) generation. OS occurs when prooxidants (e.g., ROS, NO, and lipid peroxides) outbalance antioxidant defenses (e.g., SOD, CAT, and GSH-px). OS mediates in physiological or pathological events by activating/suppressing multiple redox signaling pathways (e.g., Nrf-2, MAPK, NF-κB, PI3K/Akt, and JAK-STA). For example, high-level OS may induce the damage of macromolecules (DNA, proteins, and lipids), organelles (mitochondria and membranes), and even the whole tissues, whereas low-level OS may contribute to cell survival. In this process, ROS, including radical and nonradical ROS such as O2•-, •OH, R-O2•, O3, HOCl, and H2O2, play a pivotal role in the generation of OS. ⊕ means “to promote or enhance”; ⊖ means “to inhibit or suppress.”
2. Role of OS in Angiogenesis
With further knowledge of angiogenesis, the pathogenesis of angiogenesis to some extent gradually becomes clear. It arrives at a consensus that ROS-mediated OS plays a crucial role in the development of angiogenesis. Moreover, two signal pathways of angiogenesis mediated by OS have been identified. One is the VEGF-dependent signaling pathway, while another is the VEGF-independent pathway [10, 39, 40].
2.1. Generation of ROS in Angiogenesis
At present, it is demonstrated that ROS-mediated redox signaling has a central role in angiogenesis. ROS act as a double-edged sword in the vasculature. In a physiological process, ROS work as an important component of signaling events and play an important role in cellular differentiation and maintenance of homeostasis [41]. However, overproduction of ROS (O-2 and H2O2) in turn contributes to neovascularization [21]. In this process, two endogenous ROS sources are mainly involved in the angiogenesis; one is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase of the NOX family, and another is mitochondrial electron transport chain reactions [21, 31, 42, 43]. NADPH oxidase, a major source of ROS in ECs, generates O2•- by transferring electrons from NADPH to oxygen. There are seven isoforms of NADPH oxidases expressed in mammals, namely, Nox1, Nox2 (previously gp91phox), Nox3, Nox4, Nox5, Duox1, and Duox2. This NADPH oxidase homologue consists of the following subunits: gp91phox (newly termed Nox2), p22phox, p40phox, p47phox, p67phox, and GTPase Rac1 [35, 44–46]. NADPH oxidase may be activated by diverse growth factors including VEGF, angiopoietin-1, ischemia, and hypoxia, and then, ROS derived from NADPH oxidase mediate in VEGFR-2 autophosphorylation [45, 47]. Apart from NADPH oxidase, ROS, the intracellular ROS in particular, were as well originated from the mitochondria. In the mitochondria, over 95% of oxygen consumed by cells affords water molecule production via redox reactions. But at complexes I and III in the transport chain, less than 4% of oxygen, which is reduced to superoxide anion instead of water, can generate OS [31, 45].
2.2. OS and Physiological Angiogenesis
Angiogenesis is physiologically essential for skin renewal, wound healing, tissue repair, skeletal remodeling, individual reproduction, etc. Among these physiological events, wound healing is a typical process involving angiogenesis and OS [20]. In this process, angiogenesis is induced by tissue hypoxia and ROS in either a VEGF-dependent way or a VEGF-independent way [48]. Low-concentration ROS facilitate angiogenesis in mouse wound healing and skin repair, which are involved in VEGF and its receptor signaling [49]. As the potent inducer of VEGF, hypoxia inducible factor 1 (HIF1) activated by ROS promotes angiogenesis via triggering VEGF expression during wound repair [50]. Thus, angiogenesis could be induced by ROS-mediated OS in a VEGF-dependent manner in wound healing. Increasing evidence has verified that VEGF can promote angiogenesis via binding to VEGF receptor-2 (VEGFR-2) in endothelial cells. The binding of VEGF to VEGFR-2 allows to activate a series of signal transduction molecules, including phospholipase C gamma (PLCγ) and phosphatidylinositol 3-kinase (PI3K), further stimulates the Raf-MAPK-ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) pathway, and finally facilitates angiogenesis [51, 52]. It is therefore considered that VEGF/VEGFR-2 signaling is a crucial signal transducer in both physiologic and pathologic angiogenesis. Apart from VEGF, other soluble factors like PDGF play an important role in angiogenesis during wound healing, which is dependent on H2O2 for its biological function [53]. Upon activation of the PDGF pathway, signaling occurs via the PI3K/Akt complex pathway and MAPK molecules [54]. Besides, endogenous 2-ω-carboxyethyl pyrrole (CEP), one major member of the carboxyalkyl pyrrole (CAP) family, is recognized by Toll-like receptor2 (TLR2) on endothelial cells and then activates MyD88-dependent signaling to promote angiogenesis at the wound site, which, in turn, accelerates wound healing. Consequently, OS also acts as the chief mediator of the VEGF-independent pathway in angiogenesis during the wound repair process [10].
2.3. OS and Pathological Angiogenesis
Pathological angiogenesis, fundamentally similar to physiological angiogenesis, is also affected by OS in VEGF-dependent and VEGF-independent ways, which proceeds in an unbalanced and uncontrolled fashion, finally resulting in an excessive and abnormal vascular pattern [55].
2.3.1. VEGF-Dependent Signaling Pathway
As one of the major angiogenesis factors, VEGF stimulates EC proliferation and migration via binding to VEGFR-2 regardless of physiological status or pathological condition, further activates several downstream signaling cascades, such as mitogen-activated protein kinases (MAPKs), PI3k/AKT, or eNOS, and eventually leads to physiological or pathological angiogenesis. Physiological angiogenesis like wound angiogenesis has been discussed before, and the mechanism of pathological angiogenesis is as follow.
The VEGF signal is essential for homeostasis and vascular development, which is always influenced by ROS [35]. Increasing evidence has indicated that most OS-related angiogenesis depends on VEGF involvement. Xia et al. showed that NADPH oxidase-dependent ROS stimulated VEGF secretion and facilitated excessive angiogenesis in a tumor microenvironment through the HIF-1α-mediated VEGF pathway, further promoting tumor growth [56]. ROS from follicle-stimulating hormone (FSH) triggered HIF-1α signal and activated the VEGF signaling pathway by binding HIF-1α to the VEGF promoter and further accelerated excessive angiogenesis and finally contributed to ovarian epithelial cancer progression [57]. Likewise, products of oxidation exemplified by oxidized phospholipids (OxPLs) stimulate VEGF expression both in vivo and in vitro, thereby interacting with VEGFR-2 and triggering angiogenesis [58]. Especially, oxidized low-density lipoproteins (OxLDL) originated from OS could strongly induce HIF-1a and VEGF expression in monocyte macrophages and significantly enhance tube formation in cocultured endothelial cells [59–61]. As Toll-like receptor (TLR) ligands, poly (I:C) and lipopolysaccharide (LPS) both generated from OS, are also able to encourage angiogenesis via stimulating VEGF secretion or production and activate HIF-1α and the TLR pathway in a TLR-dependent manner [55, 62]. In addition, nitric oxide (NO) is considered to be one of the major contributors to angiogenesis and it has a capability of increasing the expression of HIF-1α and VEGF, thereby leading to angiogenesis [63]. Thus, ROS-promoting angiogenesis is dependent on VEGF and the HIF-1α/VEGF/VEGFR-2 pathway is a key molecular mechanism of OS-mediated angiogenesis [60].
2.3.2. VEGF-Independent Signaling Pathway
Apart from the VEGF-dependent pathway, another novel mechanism of OS-mediated angiogenesis in a VEGF-independent manner recently has been demonstrated. Nowadays, because of some malignant tumors being resistant to anti-VEGF therapy, it is widely considered that the existence of VEGF-independent signaling is mainly responsible for this treatment-resistant event. In most cases, this resistance to anti-VEGF is linked with inflammation and infiltration of myeloid cells, which could create substantial oxygen tension and result in the accumulation of CEPs and finally accelerate neovascularization in a VEGF-independent manner [10]. There are two main VEGF-independent signaling pathways involved in angiogenesis, the CEP/TLR2/MyD88 axis and ROS/ataxia-telangiectasia mutated (ATM)/p38α pathways [10, 64]. The former mediates proangiogenesis and involves the accumulation of new lipid oxidation products, e.g., CAP protein adducts [55, 65]. CEP acts as a potential biomarker for OS-induced vascular disorders and has the same proangiogenic effect as VEGF in vitro [66]. It has been demonstrated that TLRs not only serve as guardians of innate immunity but also function as prominent contributors to angiogenesis [67]. At present, it has been discovered that several proangiogenic ligands of TLRs produced by OS promote angiogenesis in a VEGF-independent way, such as CEP (a TLR2 ligand), macrophage-activating lipopeptide-2 (MALP-2) (a TLR2/6 ligand), and LPS (a TLR4 ligand). The molecular pattern of CEP, for example, is recognized by TLR2 on endothelial cells and triggers the MyD88-dependent signal to accelerate neovascularization [68]. LPS could stimulate endothelial sprouting directly in vitro through a TRAF6-mediated activation of NF-κB and JNK [69]. Angiogenesis is also induced via GM-CSF by TLR2/6 ligand binding to its receptor [70–72].
On the other hand, the latter, namely, ATM kinase, known for its function in the regulation of cell cycle and DNA damage repair, has been identified as an alternative mediator of OS-induced angiogenesis [73–75]. Remarkably, compared to CEP-TLR2 in angiogenesis, ATM in angiogenesis is uniquely limited to promoting the pathological process and ATM activation enhances no other cells but endothelial cell proliferation, which provides a probability for anti-ATM therapy [73]. As the downstream of ATM in endothelial cells, p38 is also involved in response to ROS; diminishing of ATM also suppressed angiogenesis even in the absence of VEGF inhibitors, suggesting a VEGF-independent proangiogenic role of ATM [73]. Figure 2 sketches two pathways of OS-mediated angiogenesis.
Schematic illustration of angiogenesis signaling pathways induced by OS. According to different responses to OS, two signal pathways of angiogenesis are covered, namely, the VEGF-dependent signaling pathway and VEGF-independent signaling pathway. In the VEGF-dependent pathway, ROS, NO, OxLDL, and OxPLs strongly stimulate the expression of HIF-1a and VEGF. Meanwhile, Poly I:C and LPS promote the expression of HIF-1α and VFGF by coupling with their specific receptors (TLR3 and TLR4). These further combine to the downstream receptor VEGFR-2 and facilitate angiogenesis by activating the HIF-1α/VFGF/VEGFR-2 signaling pathway in a VEGF-dependent manner. On the other hand, many mediators are involved in the VEGF-independent pathway, including CEP, LPS, MALP-2, PDGF, and ROS. CEP/yyMALP-2 initially couples to their receptors (TLR2/6), then sensitizes specific downstream targets (e.g., MyD88 and GM-CSF), and finally promotes angiogenesis. Meanwhile, ROS activate the P38 pathway via inducing the activation of ATM and ultimately result in angiogenesis. Besides, LPS is considered to induce angiogenesis through a TRAF6-mediated activation of NF-κB and JNK. As another soluble mediator, PDGF triggers PI3K/Akt and MAPK signaling by binding to its receptor and promotes neovascularization.
3. OS and Angiogenesis in Dermatoses
Growing evidence supports that OS and angiogenesis are both closely implicated in the occurrence and development of some skin diseases, such as psoriasis, AD, malignant melanoma (MM), Behcet’s disease (BD), and scleroderma. However, the specific mechanism still remains unclear; thus, we concentrate on recent findings to present the possible mechanism of OS and angiogenesis in these cutaneous diseases.
3.1. OS and Angiogenesis Associated with Psoriasis
Psoriasis is a common chronic inflammatory skin disease approximately affecting 2% of the population. It characteristically manifests as erythema and papules/plaques accompanied by thick silvery-white scales. Nowadays, there is a wide range of options available for the treatment of psoriasis, such as topical therapies, phototherapy, older small-molecule systemic agents (e.g., methotrexate, cyclosporine, acitretin, and fumaric acid), the newer oral phosphodiesterase-4 inhibitor apremilast, and the biologics (e.g., etanercept, adalimumab, infliximab, and ustekinumab) [76]. Despite that these therapies offer a certain efficacy, patients scarcely get satisfaction with substantial psoriatic lesion clearance, symptom relief, and improvements in quality of life [77]. Thus, there is a pressing need to develop some novel effective remedies. Although the etiology of psoriasis still remains unclear, it is thought that oxidative and angiogenic mechanisms both get involved in the pathological process of psoriasis. As one of major pathological features of psoriasis, angiogenesis has been persistently studied and various proangiogenic mediators have been identified in the psoriatic skin. Heidenreich et al. revealed a large spectrum of proangiogenic factors to mediate in psoriasis, including VEGF, HIF-1α, TNF, angiopoietins, IL-8, IL-17, and TGF-α [78].VEGF expression, in particular, remarkably elevated in the psoriatic serum and lesions. Moreover, ROS induced VEGF releasing from various cell types, whereas VEGF in turn promoted endothelial cell migration and proliferation through an increase of intracellular ROS. Thus, the VEGF pathway may be a crucial link between OS and angiogenesis in psoriasis, especially for the HIF-1α/VEGF signaling pathway playing a synergistic role in the neovascularization of psoriasis [79, 80]. By upregulating the expression of cell adhesion molecules, VEGF could enhance the migration of leukocytes into the psoriatic skin and increase oxygen consumption, further activating HIF-1α and perpetuating the angiogenic/inflammatory cycle of psoriasis [30, 81]. Furthermore, OxPLs afford the pathogenesis of psoriasis through enhancing VEGF generation from keratinocytes [30]. Besides, Elias et al. discovered that epidermal VEGF knockout mice scarcely appeared acanthosis after barrier disruption, suggesting an important contributor for VEGF to the development of keratinocyte hyperplasia. Hence, ROS-VEGF signaling may be a potential target for the treatment of psoriasis. However, the specific relationship between OS and angiogenesis in psoriasis requires to be further studied, which is conducive to fully clarify the pathogenesis of psoriasis and expand the optimal treatments for this disease.
3.2. OS and Angiogenesis Associated with AD
AD, a chronic inflammatory skin disease, adversely affects many people especially young children [82]. The current management of AD covers avoidance of triggering factors, skin care, and anti-inflammatory therapy (mostly topical corticosteroids and topical calcineurin inhibitors). Once these first-line approaches are unsuccessful, systemic therapy or phototherapy tends to be carried out as second-line treatment [83]. After being treated with these vehicles, most symptoms may be relieved. However, long-term use of the above therapeutic probably causes many side effects such as skin atrophy and dryness, photoaging, and potential occurrence of cutaneous malignancies [84]. Therefore, some novel therapies are needed for the management of AD. The pathogenesis of AD is complex and still poorly understood. Recently, emerging evidence suggests that OS is a potential key factor in the pathogenesis of AD [85]. OS is implicated in AD for several decades and remains present throughout the disease, including the onset of AD, the development of AD, and the exacerbation of AD. Moreover, excessive ROS overwhelm and destroy the skin antioxidant defense, which ultimately lead to AD progression and exacerbation [86]. Apart from OS, angiogenesis, as a hallmark of chronic inflammatory disorders, also gets involved in AD [87]. Several angiogenic factors contribute to the presence of angiogenic switch in the AD skin, such as VEGF, Angs, and IL-17. It has been demonstrated that angiogenesis is dysregulated in AD patients or models and high-level VEGF is detected in AD patient lesions. Meanwhile, Chen et al. discovered that a progressive increase of VEGF-A mRNA appeared in the skin of an AD mouse model [88]. Taken together, both OS and angiogenesis are mainly responsible for the pathogenesis of AD and the VEGF pathway may be a potential link between OS and angiogenesis in AD. Therefore, specific inhibitors targeting various mediators (e.g., VEGFs), receptors (e.g., VEGFRs and Tie-2), and oxides offer a promising foreground for the treatment of AD [7].
3.3. OS and Angiogenesis Associated with MM
MM, a malignant tumor of melanocytes, is accounted for about 10% of skin cancers, but it is responsible for over 90% of skin cancer deaths. For years, the cornerstones of cancer treatment have been surgery, chemotherapy, and radiation therapy. During the last decade, new strategies emerge from antitumor therapy for MM, including immunotherapy (e.g., checkpoint blockades) and targeted therapy (e.g., protein kinase inhibitors) or their combination [89]. Despite of extensive novel approaches serving for MM, the response rate is rarely higher than 20% and drug resistance is very common [90]. Up to date, rarely effective treatment has been approved for MM due to these reasons. As a result, it is urgent to invent other alternatives and targeted therapies [91, 92]. Compared to other tumors, MM is known for abundant ROS that exist in the primary tumor environment [93, 94]. ROS from OS at one time had been recognized as a powerful weapon for the immune system to kill tumor cells [95]. However, once MM cells successfully escape ROS-induced apoptosis, persistent ROS tend to favor melanoma survival, proliferation, and metastasis through activating several related pathways [96]. Thus, ROS and ROS-mediated OS are closely implicated in different stages of MM. Elevated ROS could trigger the occurrence of OS, which further disrupt the homeostasis of melanocytes, affect the epigenetic regulation, and induce gene mutation, ultimately leading to cancer generation [97]. Accordingly, much efforts have been made to battle melanoma by using antioxidants so far [98]. Moreover, ROS and ROS-mediated OS would promote MM angiogenesis in a VEGF-dependent or VEGF-independent manner; in their publication, Bald et al. as well have emphasized the importance of the vascular network for MM [99]. Several angiogenic factors (e.g., VEGF, bFGF, PIGF, PDGF, IL-8, and Ang-1) have been found to highly express in primary skin MM, and these mediators further promote MM angiogenesis and metastasis [100]. In addition, intratumoral hypoxia encourages the consequent expression of HIF-α transcription factors, in turn modulating VEGF and transcriptional product expression and mediating in cell growth, metabolism, and death [101, 102]. Meanwhile, preclinical studies indicate that the inhibitors targeting VEGF or VEGFR are effective in slowing the growth and metastasis of MM in murine models [103, 104]. Apart from VEGF, PDGF and its receptor PDGFR-β are responsible for MM angiogenesis. PDGF signaling is also implicated in angiogenesis in a VEGF-independent fashion. Therefore, OS and angiogenesis play vital roles in the development of MM; VEGF and PDGF signaling, moreover, may be the key link to OS and angiogenesis, which probably become the potential targets for the treatment of MM [105].
3.4. OS and Angiogenesis Associated with BD
BD, a chronic and recurrent vasculitis disease, is characterized by various clinical manifestations including skin lesions, oral/genital ulcer, ocular symptoms/lesions, joint signs, and organ involvements [106–108]. Glucocorticoids, azathioprine, cyclophosphamide, and cyclosporine A are currently the mainstay of treatments in vasculo-Behcet’s disease, but long-term use of these drugs may induce some systemic adverse reactions [109]. Once immunosuppressive and corticosteroid therapies fail, biologic agents (e.g., infliximab, alemtuzumab, and adalimumab) can help for vascular lesions. However, high cost may be an obstacle to their widespread application [110]. Although BD etiology keeps being unknown, recently, growing evidence supports that elevated OS and insufficient antioxidant capacity are primarily involved in the pathogenesis of BD [111–113]. In the process of BD attack, ROS overproduction from OS may in turn accelerate OS aggression, then lead to tissue damage, and ultimately result in the pathological and clinical manifestations of BD. More importantly, we have demonstrated in our previous studies that there is an abnormal OS indeed existing in BD and a skewed redox balance remains present throughout this disease [114]. Apart from the OS-mediated mechanism, vascular endothelial activation is also considered to be a major one in BD [115–117]. Nowadays, it has been confirmed that several angiogenesis-promoting molecules (namely, angiogenic promoters) get involved in the pathogenesis of BD, including IL-8, matrix metalloproteinases, E-selectin, vascular endothelial-cadherin, and VEGF [118]. Among them, VEGF, the dominant factor controlling angiogenesis, was found to highly express in BD serum and elevated-level VEGF was proportional to BD activity [119–121]. VEGF, at the same time, plays an active role in the maintenance and growth of vascular endothelial cells. Kamoun et al. thought that high-level VEGF was closely associated with high concentration of NO from OS in BD [122]. Thus, OS and angiogenesis are crucial in BD pathogenesis and OS zealously mediates in the process of angiogenesis. However, further studies are needed to investigate the underlying mechanisms of OS-mediated angiogenesis in BD, in order to develop new therapeutic strategies for BD patients to suppress OS and angiogenesis.
3.5. OS and Angiogenesis Associated with Scleroderma
Scleroderma, also known as systemic sclerosis (SSc), is a chronic immune-mediated connective tissue disease involving the skin, blood vessels, systemic organs, lungs, kidney, and gastrointestinal tract in particular [91]. SSc consists of two clinical subsets: one is limited cutaneous SSc (lc-SSc) and another is diffuse cutaneous SSc (dc-SSc). Because skin sclerosis can cause joint contracture, disability, and poor quality of life, various systemic treatments (e.g., penicillamine, cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, and tyrosine kinase inhibitors) have been applied to alleviate the symptoms. These treatments, however, may cause severe side effects and offer inconsistent efficacy [123]. Phototherapy, another approach used to relieve skin sclerosis, provides a local effect on the skin without systemic involvement, but it alone cannot completely reverse skin sclerosis and it is just used as an adjunctive therapy together with other antifibrotic treatments (i.e., corticosteroids and pentoxifylline) [124]. Recently, it is thought that OS plays an important part in promoting scleroderma development, though SSc pathogenesis remains obscure [125]. Murrell proposed that an abnormal generation of ROS should be responsible for most of the pathologic features of SSc [126]. For example, ROS could stimulate the production of profibrotic cytokines (including PDGF and TGF-β) and proinflammatory factors, accelerate the activation and proliferation of fibroblasts, promote the synthesis of type I collagen, and induce vascular dysfunction [127]. By targeting ROS-generating NADPH oxidase, fibroblast activation and experimental skin fibrosis are inhibited in vitro and in vivo [128]. On the other hand, several abnormalities in regulating angiogenic responses in scleroderma indicate that aberrant angiogenesis may be another important pathogenic factor of scleroderma [129]. Hummers et al. have found that high levels of angiogenic factors were measured in patients with scleroderma, e.g., VEGF, PDGF-BB, FGF2, and PlGF [130]. Meanwhile, increased-level VEGF and VEGFR have been discovered in the serum and skin samples from scleroderma patients [131–135]. Besides, HIF-1a is more prevalent in SSc patients than normal subjects [136]. Accordingly, the pathogenesis of scleroderma is closely associated with OS and abnormal angiogenesis but further studies focused on the link between OS and angiogenesis in SSc are still needed, which may lead to the development of a new way for scleroderma treatment.
3.6. OS and Angiogenesis Associated with Rosacea
Rosacea is a common chronic inflammatory dermatosis, clinically characterized by erythema of the central face, episodic flushing, papules, and pustules [137, 138]. Skin care and pharmacologic treatments are the pillars of effective management of rosacea. Apart from existing topical agents (sodium sulfacetamide, azelaic acid, metronidazole, and the alpha-adrenergic agonist brimonidine) and systemic medications (tetracyclines, beta-blockers and isotretinoin), new therapies including serine protease inhibitors and mast cell stabilizers may ameliorate rosacea symptoms [139]. However, some of these approaches have not been approved by the Food and Drug Administration. Though the exact pathogenesis of rosacea needs to be clarified, OS and oxidation of lipids are considered as crucial factors to trigger and aggravate the inflammatory processes of rosacea. Increased OS and decreased antioxidants are determined in systemic circulation of rosacea [140, 141]. OS, in addition, is complicated in vascular changes, inflammation, and oxidative tissue damage in rosacea [142]. Therefore, antioxidants may be a potential strategy for treating rosacea. As an essential process in chronic inflammatory dermatoses, angiogenesis also contributes to the development of rosacea [143–145]. Amal et al. reported that VEGF expression elevated in cutaneous lesions of rosacea and was consistent with vascular histological changes which clinically presented as erythema and telangiectasia [146]. VEGF, indeed, has an important impact on the angiogenesis process, responsible for telangiectasia and increased vascular permeability, leading to cutaneous inflammation and the presence of papules, pustules, and nodules in rosacea [147, 148]. Thus, attenuation of OS and VEGF may be relevant approaches for the therapy of rosacea. However, more research should be carried out to clarify the relationship of OS and angiogenesis and provide a novel therapeutic way for rosacea.
4. Therapeutic Implications
Given that OS and OS-mediated angiogenesis have important roles in promoting various dermatoses, it should be fully suitable to develop novel therapies for skin disorders aimed at both aspects (Figure 3). As a major regulator of angiogenesis, VEGF and its pathway are considered as key targets for antiangiogenic therapy [149, 150]. Some effective drugs targeting VEGF have emerged from the pharmaceutical industry to inhibit new vessel formation.
Strategies for dermatoses through mediating OS-induced angiogenesis and OS. Several novel therapies used for OS or angiogenesis-related skin disorders have been developed, including antiangiogenic agents, agents against OS, and natural plant extracts. These vehicles are potentially effective in management of dermatoses (e.g., psoriasis, AD, MM, scleroderma, BD, and rosacea) through mediating OS or angiogenesis-associated signal pathways.
4.1. Antiangiogenic Agents in the Management of Skin Diseases
Based on successful phase III trials, antiangiogenic therapeutics, anti-VEGF agents in particular (e.g., sorafenib, bevacizumab, and sunitinib), have entered the clinical practice in the USA and elsewhere. Strategies have been developed to inhibit the VEGF signaling pathway including anti-VEGF antibody therapy (e.g., bevacizumab), anti-VEGFR antibody therapy (e.g., ramucirumab), inhibitors of VEGFR-2 tyrosine kinases (e.g., apatinib), and inhibitors of angiogenic receptor tyrosine kinases (e.g., sunitinib, pazopanib, sorafenib, and regorafenib) [151]. Due to their antiangiogenic, antioxidative, and antiproliferative effects, phytochemicals are beneficial in the battle against cutaneous carcinoma [152]. Intraperitoneal injection of recombinant thrombospondin type 1 repeat domain (rTSR1) or a disintegrin-like and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) could potently inhibit subcutaneous melanoma growth by diminishing angiogenesis, promoting apoptosis, and decreasing cell proliferation in the tumor tissue [153]. Antiangiogenic agent AE-941 from extracts of cartilage potentially provides a beneficial effect to treat cutaneous and systemic diseases especially for psoriasis [154]. It is speculated that cannabinoids have a potential role in treatment of psoriasis by controlling angiogenesis and inflammation through decreasing HIF-1α and VEGF levels [155]. Meanwhile, Kuang et al. also demonstrated that topical sunitinib ointment contributed to attenuate imiquimod-induced psoriasis-like inflammation through regulating the proliferation and apoptosis of keratinocytes via suppressing p-Stat3 and VEGF expression [156]. Besides, thalidomide effectively works in skin disorders such as BD through inhibition of VEGF- and FGF-2-mediated angiogenesis [157].
4.2. Agents against OS in the Management of Dermatoses
On the other side, it is quite beneficial to skin disorder recovery by employing OS-targeted drugs like antioxidants. Because OS-dependent angiogenesis is an important contributor to the progression of cancers, antioxidants may overcome the limitations of anti-VEGF therapy, especially in relation to tumor resistance. Related documents revealed that glabridin ameliorated imiquimod-induced psoriasis-like inflammation on BALB/c mice skin through improvement of antioxidant status and downregulation of proinflammatory cytokines [158]. By decreasing lipid peroxidation and modulating Ca2+ release, colchicine significantly induced protective effects on OS in the neutrophils of BD patients [159]. More importantly, high-dose vitamin C could effectively work in the skin diseases of MM and AD owing to its antioxidant protection [160]. Apart from the traditional antioxidants, NADPH oxidase, a key enzyme generation of ROS in neovascularization, potentially becomes the important target of pharmacological inhibitors. And NOX inhibitors are the most promising therapeutic option for diseases associated with OS. Among them, traditional NADPH oxidase inhibitors, such as apocynin and diphenylene iodonium, have no specificity and little isoform selectivity. Instead, several novel NOX inhibitors (GKT137831, ML171, and VAS2870) exhibit improved specificity for NADPH oxidases and NOX isoform selectivity [161].
4.3. Natural Plant Extracts in the Management of Dermatoses
Nowadays, natural extracts from plants increasingly arrest the attention from medical fields and pharmaceutical industry. Numerous natural extracts, like tea polyphenol, proanthocyanidins, and allicin, are potently beneficial to various skin disorders. As the main active ingredient of tea polyphenol, epigallocatechin-3-gallate (EGCG) could prevent OS-induced damage and suppress angiogenesis to avail against skin cancer and psoriasis basing on its antioxidant, antitumor, and antiangiogenic properties [162, 163]. Due to their powerful antioxidation, antiangiogenesis, antiproliferation, and antioncogenesis, proanthocyanidins have a wide utilization in the management of various OS-related and angiogenic complaints [164, 165]. Phenolic metabolites [166]. Moreover, we have proposed in our previous publications that proanthocyanidins are good for the treatment of psoriasis, AD, allergic purpura, SSc, rosacea, skin cancer, and other dermatoses [167]. Besides, our recent finding reveals that allicin, an active substance from garlic, has a favorable efficacy on BD by attenuation of OS and balance of oxidant/antioxidant status [168].
5. Conclusion
In summary, there are two main mechanisms implicated in the area bridging angiogenesis and OS; one is the VEGF-dependent signaling pathway (HIF/VEGF signaling), while another is the VEGF-independent signaling pathway (CEP/TLR2/MyD88 axis and ROS/ATM/p38α pathway). It is clear that OS and OS-derived angiogenesis are important contributors to the progression of chronic diseases and tumors. There is no doubt that both OS and angiogenesis participate in the development of certain skin diseases; however, a deeper understanding of the mechanisms behind OS and OS-dependent angiogenesis is necessary. There is a need for an investigation of multifaceted pathways involved in OS-induced angiogenesis in dermatoses and a specific target discriminating pathological vasculature from the physiological one. Therefore, in addition to the anti-VEGF drugs and OS inhibitors or antioxidants, it is necessary to develop some newly specific target strategies.
Conflicts of Interest
No financial or other conflicting interest exists.
Authors’ Contributions
Dehai Xian and Jing Song contributed equally to this work.
Acknowledgments
The authors thank Professor Liao Li and Yang Xu for their very helpful comments on this manuscript, which is greatly beneficial to the improvement of this paper.
RosenL. S.Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers200292 Supplement364410.1177/107327480200902S05HoebenA.LanduytB.HighleyM. S.WildiersH.Van OosteromA. T.De BruijnE. A.Vascular endothelial growth factor and angiogenesis200456454958010.1124/pr.56.4.32-s2.0-1064427994715602010AdiniA.AdiniI.ChiZ.-l.DerdaR.BirsnerA. E.MatthewsB. D.D’AmatoR. J.A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P201720339940810.1007/s10456-017-9556-72-s2.0-8501721341728397127SajibS.ZahraF. T.LionakisM. S.GermanN. A.MikelisC. M.Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions201821111410.1007/s10456-017-9583-42-s2.0-8503349769229110215GranataF.FrattiniA.LoffredoS.StaianoR. I.PetraroliA.RibattiD.OslundR.GelbM. H.LambeauG.MaroneG.TriggianiM.Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2201018495232524110.4049/jimmunol.09025012-s2.0-77954511728ViallardC.LarrivéeB.Tumor angiogenesis and vascular normalization: alternative therapeutic targets201720440942610.1007/s10456-017-9562-92-s2.0-8502510300528660302GenoveseA.DetorakiA.GranataF.GaldieroM. R.SpadaroG.MaroneG.Angiogenesis, lymphangiogenesis and atopic dermatitis201296506010.1159/0003318832-s2.0-84859194082RicharzN. A.BoadaA.CarrascosaJ. M.Angiogenesis in dermatology – insights of molecular mechanisms and latest developments2017108651552310.1016/j.ad.2016.12.0012-s2.0-8501126297128162227ChungA. S.FerraraN.Developmental and pathological angiogenesis201127156358410.1146/annurev-cellbio-092910-1540022-s2.0-80054012347KimY. W.WestX. Z.ByzovaT. V.Inflammation and oxidative stress in angiogenesis and vascular disease201391332332810.1007/s00109-013-1007-32-s2.0-8487572912023430240SchremlS.SzeimiesR. M.PrantlL.KarrerS.LandthalerM.BabilasP.Oxygen in acute and chronic wound healing2010163225726810.1111/j.1365-2133.2010.09804.x2-s2.0-77954881513ReuterS.GuptaS. C.ChaturvediM. M.AggarwalB. B.Oxidative stress, inflammation, and cancer: how are they linked?201049111603161610.1016/j.freeradbiomed.2010.09.0062-s2.0-78049370987LongM.YangS. H.HanJ. X.LiP.ZhangY.DongS.ChenX.GuoJ.WangJ.HeJ. B.The protective effect of grape-seed proanthocyanidin extract on oxidative damage induced by zearalenone in Kunming mice liver201617680810.3390/ijms170608082-s2.0-85015581096FinkelT.HolbrookN. J.Oxidants, oxidative stress and the biology of ageing2000408680923924710.1038/350416872-s2.0-0034626735LushchakV. I.Environmentally induced oxidative stress in aquatic animals20111011133010.1016/j.aquatox.2010.10.0062-s2.0-7864990678921074869LushchakV. I.Free radicals, reactive oxygen species, oxidative stress and its classification201422416417510.1016/j.cbi.2014.10.0162-s2.0-84911127372YoonS. O.YunC. H.ChungA. S.Dose effect of oxidative stress on signal transduction in aging2002123121597160410.1016/S0047-6374(02)00095-72-s2.0-003686095112470897HanY.HuangC.SunX.XiangB.WangM.YehE. T. H.ChenY.LiH.ShiG.CangH.SunY.WangJ.WangW.GaoF.YiJ.SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress201028517129061291510.1074/jbc.M109.0714312-s2.0-7795123521520181954BedardK.KrauseK. H.The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology200787124531310.1152/physrev.00044.20052-s2.0-33846794822InoguchiT.SontaT.TsubouchiH.EtohT.KakimotoM.SonodaN.SatoN.SekiguchiN.KobayashiK.SumimotoH.UtsumiH.NawataH.Protein kinase C–dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase200314Supplement 3S227S23210.1097/01.ASN.0000077407.90309.65TouyzR. M.BrionesA. M.Reactive oxygen species and vascular biology: implications in human hypertension201134151410.1038/hr.2010.2012-s2.0-7865088264320981034LiN.RaghebK.LawlerG.SturgisJ.RajwaB.MelendezJ. A.RobinsonJ. P.Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production2003278108516852510.1074/jbc.M2104322002-s2.0-003742424512496265KanayamaA.MiyamotoY.Apoptosis triggered by phagocytosis-related oxidative stress through FLIPS down-regulation and JNK activation20078251344135210.1189/jlb.04072592-s2.0-3624893425117709401GorlachA.KietzmannT.HessJ.Redox signaling through NADPH oxidases: involvement in vascular proliferation and coagulation2002973150550710.1111/j.1749-6632.2002.tb04691.x2-s2.0-0036963969ChiarugiP.PaniG.GiannoniE.TaddeiL.ColavittiR.RaugeiG.SymonsM.BorrelloS.GaleottiT.RamponiG.Reactive oxygen species as essential mediators of cell adhesion2003161593394410.1083/jcb.2002111182-s2.0-0037780966ThannickalV. J.FanburgB. L.Reactive oxygen species in cell signaling20002796L1005L102810.1152/ajplung.2000.279.6.L1005van WeteringS.van BuulJ. D.QuikS.MulF. P.AnthonyE. C.ten KloosterJ. P.CollardJ. G.HordijkP. L.Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells2002115Part 91837184611956315San MartinA.GriendlingK. K.Redox control of vascular smooth muscle migration201012562564010.1089/ars.2009.28522-s2.0-76249110094MuP.LiuQ.ZhengR.Biphasic regulation of H2O2 on angiogenesis implicated NADPH oxidase201034101013102010.1042/CBI200900922-s2.0-7795732885320575760ArmstrongA. W.VoylesS. V.ArmstrongE. J.FullerE. N.RutledgeJ. C.Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis20116311910.1016/j.jdermsci.2011.04.0072-s2.0-7995755134021600738Ushio-FukaiM.AlexanderR. W.Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase20042641/2859710.1023/B:MCBI.0000044378.09409.b52-s2.0-554423771615544038YangL.XianD.XiongX.LaiR.SongJ.ZhongJ.Proanthocyanidins against oxidative stress: from molecular mechanisms to clinical applications201820181110.1155/2018/85841362-s2.0-850457693998584136auf dem KellerU.KuminA.BraunS.WernerS.Reactive oxygen species and their detoxification in healing skin wounds200611110611110.1038/sj.jidsymp.56500012-s2.0-33748808680Ushio-FukaiM.Redox signaling in angiogenesis: role of NADPH oxidase200671222623510.1016/j.cardiores.2006.04.0152-s2.0-33745217132Ushio-FukaiM.NakamuraY.Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy20082661375210.1016/j.canlet.2008.02.0442-s2.0-4444912513218406051WarisG.AhsanH.Reactive oxygen species: role in the development of cancer and various chronic conditions2006511410.1186/1477-3163-5-142-s2.0-3374526520716689993ZhaoW.ZhaoT.ChenY.AhokasR. A.SunY.Reactive oxygen species promote angiogenesis in the infarcted rat heart200990662162910.1111/j.1365-2613.2009.00682.x2-s2.0-7144909823319758416MaulikN.DasD. K.Redox signaling in vascular angiogenesis20023381047106010.1016/S0891-5849(02)01005-52-s2.0-003710820112374616ColavittiR.PaniG.BedogniB.AnzevinoR.BorrelloS.WaltenbergerJ.GaleottiT.Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR200227753101310810.1074/jbc.M1077112002-s2.0-003647921411719508MalininN. L.WestX. Z.ByzovaT. V.Oxidation as “the stress of life”20113990691010.18632/aging.1003852-s2.0-8485666772021946568ReczekC. R.ChandelN. S.ROS-dependent signal transduction20153381310.1016/j.ceb.2014.09.0102-s2.0-8490837491225305438MaulikN.Redox regulation of vascular angiogenesis20024578378410.1089/1523086027605989272-s2.0-003677625312470505TakacI.SchröderK.BrandesR. P.The Nox family of NADPH oxidases: friend or foe of the vascular system?2012141707810.1007/s11906-011-0238-32-s2.0-8485755094822071588LambethJ. D.NOX enzymes and the biology of reactive oxygen20044318118910.1038/nri13122-s2.0-154240644615039755BrandM. D.AffourtitC.EstevesT. C.GreenK.LambertA. J.MiwaS.PakayJ. L.ParkerN.Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins200437675576710.1016/j.freeradbiomed.2004.05.0342-s2.0-4043147798CosoS.HarrisonI.HarrisonC. B.VinhA.SobeyC. G.DrummondG. R.WilliamsE. D.SelemidisS.NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts201216111229124710.1089/ars.2011.44892-s2.0-8485985333622229841LassègueB.San MartínA.GriendlingK. K.Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system2012110101364139010.1161/CIRCRESAHA.111.2439722-s2.0-84861062943NizamutdinovaI. T.KimY. M.ChungJ. I.ShinS. C.JeongY. K.SeoH. G.LeeJ. H.ChangK. C.KimH. J.Anthocyanins from black soybean seed coats stimulate wound healing in fibroblasts and keratinocytes and prevent inflammation in endothelial cells200947112806281210.1016/j.fct.2009.08.0162-s2.0-7035019803019733615RoyS.KhannaS.NalluK.HuntT. K.SenC. K.Dermal wound healing is subject to redox control200613121122010.1016/j.ymthe.2005.07.6842-s2.0-2884447457816126008HeunY.PogodaK.AntonM.PircherJ.PfeiferA.WoernleM.RibeiroA.KameritschP.MykhaylykO.PlankC.KroetzF.PohlU.MannellH.HIF-1α dependent wound healing angiogenesis in vivo can be controlled by site-specific lentiviral magnetic targeting of SHP-220172571616162710.1016/j.ymthe.2017.04.0072-s2.0-8501865064628434868BoschJ.AbraldesJ. G.FernándezM.García-PagánJ. C.Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension201053355856710.1016/j.jhep.2010.03.0212-s2.0-77955853856GuoD.MurdochC. E.LiuT.QuJ.JiaoS.WangY.WangW.ChenX.Therapeutic angiogenesis of Chinese herbal medicines in ischemic heart disease: a review2018942810.3389/fphar.2018.00428LeiH.KazlauskasA.Detection of H2O2-mediated phosphorylation of kinase-inactive PDGFRα201352818919410.1016/B978-0-12-405881-1.00011-22-s2.0-84880322535XiaoY.PengH.HongC.ChenZ.DengX.WangA.YangF.YangL.ChenC.QinX.PDGF promotes the Warburg effect in pulmonary arterial smooth muscle cells via activation of the PI3K/AKT/mTOR/HIF-1α signaling pathway20174241603161310.1159/0004794012-s2.0-8502645913928738389SalomonR. G.Structural identification and cardiovascular activities of oxidized phospholipids2012111793094610.1161/CIRCRESAHA.112.2753882-s2.0-84866536186XiaC.MengQ.LiuL. Z.RojanasakulY.WangX. R.JiangB. H.Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor20076722108231083010.1158/0008-5472.CAN-07-07832-s2.0-3634893888418006827ZhangZ.WangQ.MaJ.YiX.ZhuY.XiX.FengY.JinZ.Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via NRF2 and HIF1α signaling in human epithelial ovarian cancer20132941429143410.3892/or.2013.22782-s2.0-8487473053923404377BirukovaA. A.LeeS.StarostaV.WuT.HoT.KimJ.BerlinerJ. A.BirukovK. G.A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations20127110.1371/journal.pone.00309572-s2.0-84856408598SalomonssonL.PetterssonS.EnglundM. C. O.WiklundO.OhlssonB. G.Post-transcriptional regulation of VEGF expression by oxidised LDL in human macrophages2002321076777410.1046/j.1365-2362.2002.01072.x2-s2.0-003643028212406026HutterR.SpeidlW. S.ValdiviezoC.SauterB.CortiR.FusterV.BadimonJ. J.macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1α Activation: a novel aspect of angiogenesis in atherosclerosis20136455856910.1007/s12265-013-9469-92-s2.0-8488051241423661177ShatrovV. A.SumbayevV. V.ZhouJ.BrüneB.Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1α (HIF-1α) accumulation via redox-dependent mechanisms2003101124847484910.1182/blood-2002-09-271112586627PaoneA.GalliR.GabelliniC.LukashevD.StaraceD.GorlachA.de CesarisP.ZiparoE.del BufaloD.SitkovskyM. V.FilippiniA.RiccioliA.Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1α201012753954910.1593/neo.921062-s2.0-7795499565020651983LuX.KassabG. S.Nitric oxide is significantly reduced in ex vivo porcine arteries during reverse flow because of increased superoxide production2004561257558210.1113/jphysiol.2004.0752182-s2.0-1064423547915579542KimY. W.ByzovaT. V.Oxidative stress in angiogenesis and vascular disease2014123562563110.1182/blood-2013-09-5127492-s2.0-8489695833224300855CrabbJ. W.MiyagiM.GuX.ShadrachK.WestK. A.SakaguchiH.KameiM.HasanA.YanL.RaybornM. E.SalomonR. G.HollyfieldJ. G.Drusen proteome analysis: an approach to the etiology of age-related macular degeneration20029923146821468710.1073/pnas.2225518992-s2.0-1114425854312391305EbrahemQ.RenganathanK.SearsJ.VasanjiA.GuX.LuL.SalomonR. G.CrabbJ. W.Anand-ApteB.Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: implications for age-related macular degeneration200610336134801348410.1073/pnas.06015521032-s2.0-3374860587416938854BordonY.A new vein of TLR biology2010101174810.1038/nri28752-s2.0-7804926218121080611WestX. Z.MalininN. L.MerkulovaA. A.TischenkoM.KerrB. A.BordenE. C.PodrezE. A.SalomonR. G.ByzovaT. V.Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands2010467731897297610.1038/nature094212-s2.0-7804925035020927103PolletI.OpinaC. J.ZimmermanC.LeongK. G.WongF.KarsanA.Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-κB and c-Jun N-terminal kinase200310251740174210.1182/blood-2003-01-02882-s2.0-0042442087GroteK.SchuettH.SalgueroG.GrothusenC.JagielskaJ.DrexlerH.MuhlradtP. F.SchiefferB.Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration2010115122543255210.1182/blood-2009-05-2244022-s2.0-7795055496220056792PalmN. W.MedzhitovR.Pattern recognition receptors and control of adaptive immunity2009227122123310.1111/j.1600-065X.2008.00731.x2-s2.0-58049220365KawaiT.AkiraS.Pathogen recognition with Toll-like receptors200517433834410.1016/j.coi.2005.02.0072-s2.0-2054447421015950447OkunoY.Nakamura-IshizuA.OtsuK.SudaT.KubotaY.Pathological neoangiogenesis depends on oxidative stress regulation by ATM20121881208121610.1038/nm.28462-s2.0-8486470174822797809GuoZ.KozlovS.LavinM. F.PersonM. D.PaullT. T.ATM activation by oxidative stress2010330600351752110.1126/science.11929122-s2.0-7795819159920966255BakkenistC. J.KastanM. B.DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation2003421692249950610.1038/nature013682-s2.0-003747292412556884LadizinskiB.LeeK. C.WilmerE.AlaviA.MistryN.SibbaldR. G.A review of the clinical variants and the management of psoriasis201326627128410.1097/01.ASW.0000429778.10020.672-s2.0-8487940279323669329BakerC.MackA.CooperA.FischerG.ShumackS.SidhuS.SoyerP.WuJ.ChanJ.NashP.RawlinM.RadulskiB.FoleyP.Treatment goals for moderate to severe psoriasis: an Australian consensus201354214815410.1111/ajd.120142-s2.0-8487629638223330815HeidenreichR.RöckenM.GhoreschiK.Angiogenesis drives psoriasis pathogenesis200990323224810.1111/j.1365-2613.2009.00669.x2-s2.0-6554913930619563608CampanatiA.GoteriG.SimonettiO.GanzettiG.GiuliodoriK.GiulianoA.SabatoS.StramazzottiD.GuliniE.DusiD.de BlasioS.FabrisG.OffidaniA.Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation200922237137710.1177/0394632009022002142-s2.0-67650507115NofalA.Al-MakhzangyI.AttwaE.NassarA.AbdalmoatiA.Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control200923780380610.1111/j.1468-3083.2009.03181.x2-s2.0-6674917830619309427DetmarM.BrownL. F.SchönM. P.ElickerB. M.VelascoP.RichardL.FukumuraD.MonskyW.ClaffeyK. P.JainR. K.Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice199811111610.1046/j.1523-1747.1998.00262.x2-s2.0-71442643989665379SidburyR.DavisD. M.CohenD. E.CordoroK. M.BergerT. G.BergmanJ. N.ChamlinS. L.CooperK. D.FeldmanS. R.HanifinJ. M.KrolA.MargolisD. J.PallerA. S.SchwarzenbergerK.SilvermanR. A.SimpsonE. L.TomW. L.WilliamsH. C.ElmetsC. A.BlockJ.HarrodC. G.BegolkaW. S.EichenfieldL. F.American Academy of DermatologyGuidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents201471232734910.1016/j.jaad.2014.03.0302-s2.0-8490472924424813298Ortiz-SalvadorJ. M.Pérez-FerriolsA.Phototherapy in atopic dermatitis2017996Cham, SwitzerlandSpringer279286Advances in Experimental Medicine and Biology10.1007/978-3-319-56017-5_23RodenbeckD. L.SilverbergJ. I.SilverbergN. B.Phototherapy for atopic dermatitis201634560761310.1016/j.clindermatol.2016.05.0112-s2.0-8501469004027638440OmataN.TsukaharaH.ItoS.OhshimaY.YasutomiM.YamadaA.JiangM.HiraokaM.NambuM.DeguchiY.MayumiM.Increased oxidative stress in childhood atopic dermatitis200169222322810.1016/S0024-3205(01)01124-92-s2.0-003537110811441912JiH.LiX. K.Oxidative stress in atopic dermatitis201620168272146910.1155/2016/27214692-s2.0-84960968941NguyenA.HoangV.LaquerV.KellyK. M.Angiogenesis in cutaneous disease: part I200961692194210.1016/j.jaad.2009.05.0522-s2.0-7154911451419925924ChenL.MarbleD. J.AghaR.PetersonJ. D.BeckerR. P.JinT.LiJ.ChanL. S.The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis2008151496410.1080/107396807014184162-s2.0-3804916174417952801Valko-RokytovskaM.BruchataK.SimkovaJ.MilkovicovaM.KosteckaZ.Current trends in the treatment of malignant melanoma201663333334110.4149/301_151015N5332-s2.0-84969677922KlinacD.GrayE. S.MillwardM.ZimanM.Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring201335410.3389/fonc.2013.000542-s2.0-84879679714FerreliC.GaspariniG.ParodiA.CozzaniE.RongiolettiF.AtzoriL.Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review201753330633610.1007/s12016-017-8625-42-s2.0-8502374036328712039RigelD. S.RussakJ.FriedmanR.The evolution of melanoma diagnosis: 25 years beyond the ABCDs201060530131610.3322/caac.200742-s2.0-7795693173520671054FruehaufJ. P.TrappV.Reactive oxygen species: an Achilles’ heel of melanoma?20088111751175710.1586/14737140.8.11.17512-s2.0-60849115894RicoteM.GlassC.PPARs and molecular mechanisms of transrepression20071771892693510.1016/j.bbalip.2007.02.0132-s2.0-3454760389517433773HuD. E.BrindleK. M.Immune cell-induced synthesis of NO and reactive oxygen species in lymphoma cells causes their death by apoptosis2005579132833284110.1016/j.febslet.2005.03.0992-s2.0-1944436340415907488LeiterU.SchmidR. M.KaskelP.PeterR. U.KrahnG.Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma2000292522523210.1007/s0040300504792-s2.0-003406269510867810VenzaM.VisalliM.BeninatiC.De GaetanoG. V.TetiD.VenzaI.Cellular mechanisms of oxidative stress and action in melanoma201520151148178210.1155/2015/4817822-s2.0-84929630476ObradorE.Liu-SmithF.DellingerR. W.SalvadorR.MeyskensF. L.EstrelaJ. M.Oxidative stress and antioxidants in the pathophysiology of malignant melanoma201810.1515/hsz-2018-032730352021BaldT.QuastT.LandsbergJ.RogavaM.GloddeN.Lopez-RamosD.KohlmeyerJ.RiesenbergS.van den Boorn-KonijnenbergD.Hömig-HölzelC.ReutenR.SchadowB.WeighardtH.WenzelD.HelfrichI.SchadendorfD.BlochW.BianchiM. E.LugassyC.BarnhillR. L.KochM.FleischmannB. K.FörsterI.KastenmüllerW.KolanusW.HölzelM.GaffalE.TütingT.Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma2014507749010911310.1038/nature131112-s2.0-8489587102324572365StreitM.DetmarM.Angiogenesis, lymphangiogenesis, and melanoma metastasis200322203172317910.1038/sj.onc.12064572-s2.0-0038456130MizukamiY.JoW.-S.DuerrE.-M.GalaM.LiJ.ZhangX.ZimmerM. A.IliopoulosO.ZukerbergL. R.KohgoY.LynchM. P.RuedaB. R.ChungD. C.Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells200511999299710.1038/nm12942-s2.0-2474443866316127434SparmannA.Bar-SagiD.Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis20046544745810.1016/j.ccr.2004.09.0282-s2.0-794422309815542429LiY.WangM. N.LiH.KingK. D.BassiR.SunH.SantiagoA.HooperA. T.BohlenP.HicklinD. J.Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis2002195121575158410.1084/jem.200200722-s2.0-003712433312070285OkuT.TjuvajevJ. G.MiyagawaT.SasajimaT.JoshiA.JoshiR.FinnR.ClaffeyK. P.BlasbergR. G.Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts19985818418541929751633BasuB.BiswasS.WrigleyJ.SirohiB.CorrieP.Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies20099111583159810.1586/era.09.1352-s2.0-71949095641NairJ. R.MootsR. J.Behcet’s disease2017171717710.7861/clinmedicine.17-1-712-s2.0-8501602367828148585AlpsoyE.Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions201643662063210.1111/1346-8138.133812-s2.0-8496380013027075942MatM. C.SevimA.FreskoI.TüzünY.Behçet’s disease as a systemic disease201432343544210.1016/j.clindermatol.2013.11.0122-s2.0-8489887787324767193MerashliM.EidR. E.UthmanI.A review of current management of vasculo-Behcet’s2018301505610.1097/BOR.00000000000004582-s2.0-8503659044129076891McNallyT. W.DamatoE. M.MurrayP. I.DennistonA. K.BarryR. J.An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review201712113010.1186/s13023-017-0681-62-s2.0-8502440669628716038BozkurtM.YükselH.EmS.OktayogluP.YildizM.AkdenizD.NasK.Serum prolidase enzyme activity and oxidative status in patients with Behçet’s disease2014192596410.1179/1351000213Y.00000000722-s2.0-8489431619824225260SezerE. D.AksuK.CaglayanO.KeserG.KarabulutG.ErcanG.DNA damage and its relationship with other oxidative stress parameters in Behcet’s disease201232121722210.1007/s00296-010-1605-02-s2.0-84857121046DavatchiF.Chams-DavatchiC.ShamsH.ShahramF.NadjiA.AkhlaghiM.FaeziT.GhodsiZ.Sadeghi AbdollahiB.AshoftehF.MohtashamN.KavosiH.MasoumiM.Behcet’s disease: epidemiology, clinical manifestations, and diagnosis2017131576510.1080/1744666X.2016.12054862-s2.0-8500415418627351485ZhongJ. Q.XianD. H.XiongX.Expression and correlation analysis of oxidative stress, Nrf 2 and HO-1 in Behcet’s disease201630169CekmenM.EverekliogluC.ErH.InalözH. S.DoganayS.TürközY.OzerolI. H.Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome2003421187087510.1046/j.1365-4362.2003.01688.x2-s2.0-034530760714636202DireskeneliH.Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B5120016011996100210.1136/ard.60.11.9962-s2.0-003475755111602462AksuK.DonmezA.KeserG.Inflammation-induced thrombosis: mechanisms, disease associations and management201218111478149322364132HabibagahiZ.HabibagahiM.HeidariM.Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet’s disease201020215415910.3109/s10165-009-0246-1BozogluE.DincA.ErdemH.PayS.SimsekI.KocarI. H.Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet’s patients with venous thrombosis20052344248YalcinB.ArdaN.TezelG. G.ErmanM.AlliN.Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behçet’s disease200628630330617220143WahlM. L.MoserT.PizzoS. V.Angiostatin and anti-angiogenic therapy in human disease20045917310410.1210/rp.59.1.732-s2.0-2342431195KamounM.HoumanM. H.HamzaouiA.HamzaouiK.Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease200872658158710.1111/j.1399-0039.2008.01145.x2-s2.0-5594912507019054372FrechT. M.ShanmugamV. K.ShahA. A.AssassiS.GordonJ. K.HantF. N.HinchcliffM. E.SteenV.KhannaD.KayserC.DomsicR. T.Treatment of early diffuse systemic sclerosis skin disease201331166171ChaowattanapanitS.ChoonhakarnC.FoocharoenC.JulanonN.Phototherapy in systemic sclerosis: review201733629630510.1111/phpp.123312-s2.0-85026843398VonaR.GiovannettiA.GambardellaL.MalorniW.PietraforteD.StrafaceE.Oxidative stress in the pathogenesis of systemic scleroderma: an overview20182273308331410.1111/jcmm.136302-s2.0-8504575355529664231MurrellD. F.A radical proposal for the pathogenesis of scleroderma1993281788510.1016/0190-9622(93)70014-K2-s2.0-0027518266Grygiel-GórniakB.PuszczewiczM.Oxidative damage and antioxidative therapy in systemic sclerosis201420141138958210.1155/2014/3895822-s2.0-84932137133DosokiH.StegemannA.TahaM.SchnittlerH.LugerT. A.SchröderK.DistlerJ. H. W.KerkhoffC.BöhmM.Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis2017261738110.1111/exd.131802-s2.0-8500708266127576129Mulligan-KehoeM. J.SimonsM.Vascular disease in scleroderma: angiogenesis and vascular repair2008341737910.1016/j.rdc.2007.12.0062-s2.0-4034908565518329533HummersL. K.HallA.WigleyF. M.SimonsM.Abnormalities in the regulators of angiogenesis in patients with scleroderma200936357658210.3899/jrheum.0805162-s2.0-65649133084MittagM.BeckheinrichP.HausteinU. F.Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels200181429429710.1080/000155501525729762-s2.0-003478023411720181DistlerO.del RossoA.GiacomelliR.CiprianiP.ConfortiM. L.GuiducciS.GayR. E.MichelB. A.BrühlmannP.Müller-LadnerU.GayS.Matucci-CerinicM.Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers200246, article R1110.1186/ar59612453314ChoiJ. J.MinD. J.ChoM. L.MinS. Y.KimS. J.LeeS. S.ParkK. S.SeoY. I.KimW. U.ParkS. H.ChoC. S.Elevated vascular endothelial growth factor in systemic sclerosis20033071529153312858453DaviesC. A.JeziorskaM.FreemontA. J.HerrickA. L.The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis200637219019710.1016/j.humpath.2005.10.0072-s2.0-3074443881816426919MackiewiczZ.SukuraA.PovilenaitéD.CeponisA.VirtanenI.HukkanenM.KonttinenY. T.Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin200220564164612412194DistlerO.DistlerJ. H. W.ScheidA.AckerT.HirthA.RethageJ.MichelB. A.GayR. E.Müller-LadnerU.Matucci-CerinicM.PlateK. H.GassmannM.GayS.Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis200495110911610.1161/01.RES.0000134644.89917.962-s2.0-314267051715178641van ZuurenE. J.Rosacea2017377181754176410.1056/NEJMcp15066302-s2.0-85032747475AnzengruberF.CzernielewskiJ.ConradC.FeldmeyerL.YawalkarN.HäusermannP.CozzioA.MainettiC.GoldblumD.LäuchliS.ImhofL.BrandC.LaffitteE.NavariniA. A.Swiss S1 guideline for the treatment of rosacea201731111775179110.1111/jdv.143492-s2.0-8502771076728833645TwoA. M.WuW.GalloR. L.HataT. R.Rosacea: part II. Topical and systemic therapies in the treatment of rosacea201572576177010.1016/j.jaad.2014.08.0272-s2.0-8492826358825890456TakciZ.BilgiliS. G.KaradagA. S.KucukogluM. E.SelekS.AslanM.Decreased serum paraoxonase and arylesterase activities in patients with rosacea201529236737010.1111/jdv.125562-s2.0-84921504622TismaV. S.Basta-JuzbasicA.JaganjacM.BrcicL.DobricI.LipozencicJ.TatzberF.ZarkovicN.Poljak-BlaziM.Oxidative stress and ferritin expression in the skin of patients with rosacea200960227027610.1016/j.jaad.2008.10.0142-s2.0-5814933486819028405WooY. R.LimJ. H.ChoD. H.ParkH. J.Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition201617910.3390/ijms170915622-s2.0-8498848430827649161BamfordJ. T. M.Rosacea: current thoughts on origin200120319920610.1053/sder.2001.275532-s2.0-003480610411594675AroniK.TsagroniE.KavantzasN.PatsourisE.IoannidisE.A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process2008300312513110.1007/s00403-007-0816-z2-s2.0-3994908578918071725KimM.KimK.-E.JungH. Y.JoH.JeongS.-w.LeeJ.KimC. H.KimH.ChoD.ParkH. J.Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea201524968068510.1111/exd.127452-s2.0-8493919015225940661GomaaA. H. A.YaarM.EyadaM. M. K.BhawanJ.Lymphangiogenesis and angiogenesis in non-phymatous rosacea2007341074875310.1111/j.1600-0560.2006.00695.x2-s2.0-3464883037417880579TrufanovS. V.ShakhbazyanN. P.Ophthalmic rosacea: etiopathogenesis and modern treatment methods2018134312112810.17116/oftalma201813431212-s2.0-8504936990929953092CuevasP.ArrazolaJ. M.Therapeutic response of rosacea to dobesilate2005101045445616287608JainR. K.DudaD. G.ClarkJ. W.LoefflerJ. S.Lessons from phase III clinical trials on anti-VEGF therapy for cancer200631244010.1038/ncponc04032-s2.0-30944446883DudaD. G.BatchelorT. T.WillettC. G.JainR. K.VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects200713622323010.1016/j.molmed.2007.04.0012-s2.0-3424968955717462954ChanM.SjoquistK.ZalcbergJ.Clinical utility of ramucirumab in advanced gastric cancer201599310510.2147/BTT.S627772-s2.0-8494230725926451083NgC. Y.YenH.HsiaoH. Y.SuS. C.Phytochemicals in skin cancer prevention and treatment: an updated review201819410.3390/ijms190409412-s2.0-8504446340629565284RenganathanB.DurairajV.KirmanD. C.EsubontengP. K. A.AngS. K.GeR.Recombinant TSR1 of ADAMTS5 suppresses melanoma growth in mice via an anti-angiogenic mechanism201810610.3390/cancers100601922-s2.0-8504849552329891754DupontE.SavardP. E.JourdainC.JuneauC.ThibodeauA.RossN.MarenusK.MaesD. H.PelletierG.SauderD. N.Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis19982314615210.1177/1203475498002003072-s2.0-0005485030NorooznezhadA. H.NorooznezhadF.Cannabinoids: possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation201799151810.1016/j.mehy.2016.12.0032-s2.0-85006957149KuangY. H.LuY.LiuY. K.LiaoL. Q.ZhouX. C.QinQ. S.JiaX. K.WuL. S.ZhuW.ChenX.Topical sunitinib ointment alleviates psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes2018824576310.1016/j.ejphar.2018.01.0482-s2.0-8504149708429382533MaruottiN.CantatoreF. P.RibattiD.Thalidomide in treatment of connective diseases and vasculities20065831871901701343410.4081/reumatismo.2006.187LiP.LiY.JiangH.XuY.LiuX.CheB.TangJ.LiuG.TangY.ZhouW.ZhangL.DongC.ChenH.ZhangK.duZ.Glabridin, an isoflavan from licorice root, ameliorates imiquimod-induced psoriasis-like inflammation of BALB/c mice20185924325110.1016/j.intimp.2018.04.0182-s2.0-8504539158929665498KorkmazS.ErturanI.NazıroğluM.UğuzA. C.CiğB.ÖveyI. S.Colchicine modulates oxidative stress in serum and neutrophil of patients with Behçet disease through regulation of Ca2+ release and antioxidant system2011244311312010.1007/s00232-011-9404-42-s2.0-8295518750522052237WangK.JiangH.LiW.QiangM.DongT.LiH.Role of vitamin C in skin diseases2018989110.3389/fphys.2018.008192-s2.0-85049848844ByunS.LeeE.JangY. J.KimY.LeeK. W.The NADPH oxidase inhibitor apocynin inhibits UVB-induced skin carcinogenesis201625648949110.1111/exd.129892-s2.0-8496382914526914271SharmaP.Montes de OcaM. K.AlkeswaniA. R.McCleesS. F.DasT.ElmetsC. A.AfaqF.Tea polyphenols for the prevention of UVB-induced skin cancer2018341505910.1111/phpp.123562-s2.0-8503457508929044724ZhangS.LiuX.MeiL.WangH.FangF.Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice201616133410.1186/s12906-016-1325-42-s2.0-8498467040927581210LiS.XuM.NiuQ.XuS.DingY.YanY.GuoS.LiF.Efficacy of procyanidins against in vivo cellular oxidative damage: a systematic review and meta-analysis20151010, article e013945510.1371/journal.pone.01394552-s2.0-8494721990326426531BansodeR. R.KhatiwadaJ. R.LossoJ. N.WilliamsL. L.Targeting microRNA in cancer using plant-based proanthocyanidins20164410.3390/diseases4020021DziałoM.MierziakJ.KorzunU.PreisnerM.SzopaJ.KulmaA.The potential of plant phenolics in prevention and therapy of skin disorders201617216010.3390/ijms170201602-s2.0-8495877956926901191LaiR.XianD.XiongX.YangL.SongJ.ZhongJ.Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells201823113013510.1080/13510002.2018.14620272-s2.0-85053560087ZhongJ.XianD.XiongX.LiuJ.Oral allicin in the treatment of Behcet’s disease through attenuating oxidative stress: a pilot study in 20patients with mucocutaneous lesions201730114